Blog
RSS FeedPosted by Michael Wonder on 14 Dec 2023
Antengene announces inclusion of Xpovio (selinexor) in 2023 China's National Reimbursement Drug List
13 December 2023 - Antengene today announced that Xpovio (selinexor) has been added to the National Reimbursement Drug List (2023 Version) ...
Posted by Michael Wonder on 13 Dec 2023
Hutchmed announces continued inclusion of Elunate (fruquintinib) and Sulanda (surufatinib) in the National Reimbursement Drug List in China at current terms
12 December 2023 - Hutchmed today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration, ...
Posted by Michael Wonder on 11 Dec 2023
CStone announces NMPA approval of sugemalimab as first-line treatment for oesophageal squamous cell carcinoma
8 December 2023 - This marks the 13th new drug application approval obtained by CStone and sugemalimab's fourth indication approved in ...
Posted by Michael Wonder on 20 Nov 2023
Apollomics announces the first approval of vebreltinib for MET exon 14 skip non-small-cell lung cancer
16 November 2023 - Compelling clinical data serving as basis of this approval supports continued development of vebreltinib for the rest ...
Posted by Michael Wonder on 14 Nov 2023
Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer
14 November 2023 - Approval based on results from TOPAZ-1 global Phase 3 trial and a Chinese patient cohort which ...
Posted by Michael Wonder on 09 Nov 2023
CASI Pharmaceuticals announces market approval of CNCT19 by China NMPA
8 November 2023 - CASI Pharmaceuticals is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy. ...
Posted by Michael Wonder on 01 Nov 2023
CStone announces NMPA approval of sugemalimab for patients with relapsed or refractory extranodal NK/T-cell lymphoma, the first anti-PD-1/PD-L1 mAb approved for this indication
31 October 2023 - Sugemalimab is the world’s first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma indication. ...
Posted by Michael Wonder on 26 Oct 2023
ViiV Healthcare receives approval from China’s National Medical Products Administration for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment
26 October 2023 - The marketing authorisation for rilpivirine long-acting injection was received on the 18 October 2023. ...
Posted by Michael Wonder on 18 Oct 2023
Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder
18 October 2023 - Approval exemplifies commitment to broadening access for patients living with rare diseases globally. ...
Posted by Michael Wonder on 25 Sep 2023
Golidocitinib granted priority review by China NMPA for the treatment of relapsed/refractory peripheral T-cell lymphoma
21 September 2023 - Dizal announced today that the China National Medical Products Administration has granted priority review status to golidocitinib, ...
Posted by Michael Wonder on 15 Sep 2023
Dizal announces China CDE acceptance of new drug application for golidocitinib for relapsed or refractory PTCL
14 September 2023 - Dizal today announced that the Center for Drug Evaluation of the China NMPA has accepted the new ...
Posted by Michael Wonder on 04 Sep 2023
Calquence approved in China for chronic lymphocytic leukaemia
4 September 2023 - Approval based on results from ASCEND global Phase III trial and a Phase I/II local trial, ...
Posted by Michael Wonder on 30 Aug 2023
Zai Lab announces breakthrough therapy designation granted for repotrectinib for treatment of patients with NTRK positive TKI-pretreated advanced solid tumours in China
30 August 2023 - Candidate precision medicine has shown encouraging clinical activity for both ROS1 positive NSCLC and NTRK fusion-positive advanced ...
Posted by Michael Wonder on 21 Aug 2023
Innovent announces the NMPA approval of Sintbilo (tafolecimab injection) for the treatment of adult patients with primary hypercholesterolaemia and mixed dyslipidaemia
17 August 2023 - Innovent Biologics announces that China's National Medical Products Administration has approved Sintbilo (tafolecimab injection, anti-PCSK9 monoclonal ...
Posted by Michael Wonder on 18 Aug 2023
Forxiga approved in China to reduce the risk of cardiovascular death and hospitalisation in adult patients with symptomatic chronic heart failure
18 August 2023 - The first and only heart failure therapy with a proven mortality benefit now approved for patients ...